Schilder's Disease: Children & Multiple Sclerosis

What is Schilder's Disease?

Note: Schilder's disease is not the same as Addison-Schilder disease (adrenoleukodystrophy). Schilder's disease is a rare progressive demyelinating disorder which usually begins in childhood. Symptoms may include dementia, aphasia, seizures, personality changes, poor attention, tremors, balance instability, incontinence, muscle weakness, headache, vomiting, and vision and speech impairment. The disorder is a variant of multiple sclerosis.

Is there any treatment?

Treatment for the disorder follows the established standards in multiple sclerosis and includes corticosteroids, beta-interferon or immunosuppressive therapy, and symptomatic treatment.

What is the prognosis?

As with multiple sclerosis, the course and prognosis of Schilder's disease are unpredictable. For some individuals the disorder is progressive with a steady, unremitting course. Others may experience significant improvement and even remission. In some cases, Schilder's disease is fatal.

What research is being done?

The NINDS supports and conducts an extensive research program on demyelinating disorders such as Schilder's disease. Much of this research focuses on learning more about these disorders and finding ways to prevent, treat, and cure them.


National Multiple Sclerosis Society

733 Third Avenue

6th Floor

New York, NY 10017-3288

Tel: 212-986-3240 800-344-4867 (FIGHTMS)

Fax: 212-986-7981

Multiple Sclerosis Association of America

706 Haddonfield Road

Cherry Hill, NJ 08002

Tel: 856-488-4500 800-532-7667

Fax: 856-661-9797

Multiple Sclerosis Foundation

6350 North Andrews Avenue

Ft. Lauderdale, FL 33309-2130

Tel: 954-776-6805 888-MSFOCUS (673-6287)

Fax: 954-351-0630

Related NINDS Publications and Information

Multiple Sclerosis: Hope Through Research

Multiple Sclerosis (MS) information sheet compiled by the National Institute of Neurological Disorders and Stroke (NINDS).

WebMD Public Information from the U.S. National Institutes of Health


Prepared by:

Office of Communications and Public Liaison

National Institute of Neurological Disorders and Stroke

National Institutes of Health

Bethesda, MD 20892